Amneal Pharmaceuticals, Inc. announced it has received Abbreviated New Drug Application (?ANDA?) approval from the U.S. Food and Drug Administration (?FDA?) for ciprofloxacin and dexamethasone otic suspension. This product is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid, and is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.87 USD | -0.51% | +8.30% | -3.29% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.29% | 1.81B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension